About US
Contact us
-
Bayer gets European marketing authorisation for cancer drug XofigoBayer HealthCare has received marketing authorisation from the European Commission (EC) for its Xofigo (radium-223 dichloride) injection to treat patients with castration-resistant prostate cancer (CR2013/11/20
-
Lumena receives positive COMP opinion for orphan drug designation for liver drugUS-based Lumena Pharmaceuticals has announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued positive opinions for four orphan drug designations for2013/11/20
-
Two more Merck plants to fall in job-reaping planMerck's manufacturing network continues to take a beating as the drugmaker acts on its $2.5 billion cost-cutting manifesto which is slated to claim 8,500 positions worldwide in the face of patent loss2013/11/19
-
Almac Further Enhances 3rd Party Logistics Commercial Support Services for Niche/Orphan DrugsAlmac, a leading provider of contract services to the global pharmaceutical and biotech industries, announces the release of an enhanced 3rd Party Logistics (3PL) Customer Billing Application. In r2013/11/19
-
Pharma in India scrambles to appease wholesalers, chemistsNobody making or selling drugs inIndiawas happy when the government this year expanded price caps to nearly 350 drugs, but there seemed little for anyone to do. When wholesalers and retailers began ho2013/11/18
-
Medix Biochemica Announces European Launch of Antibody Production ServicesMedix Biochemica, producer of monoclonal antibodies for the global IVD industry and diagnostic rapid tests, is presenting its MedixMAB by Design and MedixMAB Manufacturing antibody production services2013/11/18
-
Merck KGaA hikes forecast, eyes deals as cost cuts keep deliveringOnce again,Merck KGaAreported a quicker-than-expected payoff from its big cost-cutting program. The German drugmaker hiked its profit forecast for the year, saying the changes it has made are deliveri2013/11/15
-
2013 FDA Approval Rates Suggest Record Year for Post-Launch SuccessA focus on hard to treat or specialist diseases is set to result in record post-launch sales for new drugs in 2013, according to newly-released report, “FDA Approval Rates: Niche Products Driving Reco2013/11/15
-
European Medicines Agency Updates on Development of its Policy on Publication and Access to Clinical Trial DataTheEuropean Medicines Agencyis currently reviewing and analysing more than 1000 comments received during the public consultation on its draft policy on publication and access to clinical trial data, w2013/11/14
-
FDA Approves Aptiom to Treat Seizures in AdultsFDA has approved Aptiom (eslicarbazepine acetate) as an add-on medication to treat seizures associated with epilepsy. Epilepsy is a brain disorder caused by abnormal or excessive activity in the brai2013/11/14